When you’re racing a giant with a blockbuster prize waiting at the finish line, your pace is going to be closely scrutinized by the punters. That is the position that Bristol-Myers Squibb finds itself in today, as investors look right past swelling profits to focus on the company’s execution of its development program for the cancer immunotherapy nivolumab.

…read more

Source: Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead?


0 No comments